Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a 52-week low, touching down at $9.74, representing a dramatic 67% decline from its 52-week high of $29.30. With a market capitalization of $897 million and negative EBITDA of -$26.8 million over the last twelve months, the company faces a challenging period marked by a significant downturn in its market valuation. Over the past year, Myriad Genetics has seen its stock price plummet by 56.6%, with particularly concerning performance metrics showing a -62.4% return over the past six months. According to InvestingPro analysis, nine analysts have recently revised their earnings expectations downward, though the company is expected to return to profitability this year. This latest price level represents a stark contrast to the company’s performance in the prior year and signals a period of heightened scrutiny from shareholders and market analysts alike. For deeper insights into MYGN’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available among 1,400+ top US stocks.
In other recent news, Myriad Genetics reported its fourth-quarter earnings, revealing revenues of $211 million, which fell slightly short of the analyst consensus of $213 million. Despite the revenue miss, the company met earnings per share (EPS) expectations with $0.03 and achieved a gross margin of 72%, surpassing the forecasted 71%. Myriad Genetics has set its 2025 revenue guidance between $840 million and $860 million, which is below the previous Street forecast of $877 million. Analysts from JPMorgan and Jefferies have adjusted their price targets for Myriad Genetics, lowering them to $12 and $11, respectively, while maintaining cautious ratings on the stock due to concerns about future growth and the recent CEO transition.
The company is undergoing a leadership change, with Sam Raha set to replace Paul Diaz as CEO, and Mark Verratti transitioning to Chief Operating Officer. Analysts at Jefferies noted ongoing challenges with Myriad’s Prolaris and GeneSight products, as well as a revised long-term growth plan. Despite these challenges, Myriad Genetics reported a 7% year-over-year revenue growth for Q4 2024 and maintains strong liquidity with $158 million. The company is focusing on strategic partnerships and product innovations to drive future growth, including a new collaboration with PathoMx for AI-enhanced testing solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.